Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

Adding to the setbacks, Eli Lilly announced that Zepbound has outperformed Novo Nordisk’s Wegovy (20.2% compared with 13.7%, respectively) in a weight-loss head-to-head study. However ...

SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens, it framed the move as a way ...

Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls in ... that we may or may not agree with, but they show their work, distinguish facts from opinions ...

University of Birmingham venture Dexter has demonstrated the power of its Dexter software platform in a study showing that people whose childhoods featured abuse, neglect or domestic abuse carry a ...

Lilly previously provided a range of $13.9 billion to $14.5 billion. The company also provided full-year 2024 guidance of $45 billion, or 32% more than 2023. "While the US incretin [hormones that help ...

Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates.

(Reuters) -Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates ... Courtney Breen said Tuesday's downbeat forecasts ...

"While the US incretin [hormones that help regulate blood sugar ... catalysts." Lilly expects its most-watched blockbuster products — GLP-1 tirzepatide products Mounjaro and Zepbound — to ...

The mean baseline blood glucose levels (expressed in mg/dL) were 88.2±9.0 for oral DehydraTECH-tirzepatide and 87.8±11.3 for injected Zepbound®, compared to the Study-ending levels of 83.2±5.7 ...